Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

21 January 2020

World 'precariously reliant' on handful of companies developing drugs to treat superbugs, report warns

Writing for the Telegraph, Anne Gulland covers the latest Antimicrobial Resistance Benchmark highlighting the reliance on just a handful of companies to develop new antibiotics.

Direct links

Read the full article

The article begins with an overview of today's antibiotic market where large drugmakers have retreated from the antibiotics field and smaller biotech companies (SMEs) have gone bankrupt due to the poor financial rewards on offer. 

The author then compares the findings of the 2020 AMR Benchmark to the WHO's latest research on current antibacterial pipelines: 

The AMR Benchmark report echoes a warning from the World Health Organization last week that a lack of private investment and innovation in the development of new antibiotics is undermining efforts to combat drug-resistant infections. 

It concludes with a quote from Phil Thomson, president of global affairs at GSK:

“It is good that the benchmark recognises our contribution, but as the report makes clear, more must be done and engagement and action from governments and other relevant stakeholders, as well as the private sector, is key.”

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved